Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu,Shuang Li,Shuang Zhang,Ying Liu,Lixia Ma,Jing Zhu,Ying Xin,Ying Wang,Changliang Yang,Ying Cheng +9 more
Reads0
Chats0
TLDR
Hematologic parameter such as systemic immune‐inflammation index (SII), neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to-lymphocytes ratio (PLR) is associated with nivolumab efficacy in advanced non‐small‐cell lung cancer (NSCLC).Abstract:
Background Explore markers to predict the clinical outcomes of checkpoint inhibitors have high unmet needs The following study investigates whether hematologic parameter such as systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) is associated with nivolumab efficacy in advanced non-small-cell lung cancer (NSCLC) Methods Advanced/metastatic NSCLC patients treated with nivolumab monotherapy for second-line or further-line treatment at Jilin Cancer Hospital between March 2016 and July 2018 were enrolled in this retrospective study The optimal cutoff values of SII, NLR, and PLR for predicting efficacy and prognosis were determined according to receiver operating characteristic (ROC) curve and the areas under the ROC curve Progression-free survival (PFS) and overall survival (OS) were calculated and compared using Kaplan-Meier method and log-rank test Prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression (PHR) analyses Results A total of 44 patients with advanced NSCLC were included; the median age was 60 (range: 43-74) The optimal cutoff value of SII/NLR/PLR predicted PFS and OS was 6035, 307, and 144 Low SII, NLR, and PLR were associated with longer PFS (HR for SII = 034, 95%CI 015-076, P = 0006; HR for NLR = 046, 95%CI 022-099, P = 0048; HR for PLR = 039, 95%CI 017-094, P = 0025) and OS (HR for SII = 016, 95%CI 005-051, P = 0005; HR for NLR = 020, 95%CI 006-062, P = 0002; HR for PLR = 020, 95%CI 006-073, P = 0008) NLR ≤ 307, PLR ≤ 144, SII ≤ 6035 were independently associated with longer PFS and OS Conclusion The SII, NLR, and PLR are promising prognostic predictor for patients with metastatic NSCLC patientsread more
Citations
More filters
Journal ArticleDOI
Role of hematological parameters in COVID-19 patients in the emergency room.
TL;DR: Leukocyte, neutrophil, platelet count, NLR and SII values can be used in the diagnosis of COVID-19.
Journal ArticleDOI
Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
TL;DR: NLR and pre-treatment PLR could serve as prognostic biomarkers in NSCLC patients treated with ICIs, however, the value of post- treatment PLR needs further to be evaluated.
Journal ArticleDOI
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Arsela Prelaj,Roberto Ferrara,Sara Elena Rebuzzi,Claudia Proto,Diego Signorelli,Giulia Galli,Alessandro De Toma,Giovanni Randon,Filippo Pagani,Giuseppe Viscardi,Marta Brambilla,Benedetta Trevisan,Monica Ganzinelli,Antonia Martinetti,Rosaria Gallucci,Rosa Maria Di Mauro,Giuliano Molino,Nicoletta Zilembo,Valter Torri,Filippo Maria de Braud,Marina Chiara Garassino,Giuseppe Lo Russo +21 more
TL;DR: EPSILoN, combining five baseline clinical/blood parameters (ECOG PS, smoking, liver metastases, LDH, NLR), may help to identify advanced non-small-cell lung cancer (aNSCLC) patients who most likely benefit from immune checkpoint inhibitors (ICIs).
Journal ArticleDOI
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
TL;DR: This review focuses on clinical, laboratory and genetic markers which can be helpful to predict patients’ outcome and tumor response to ICI and should be implemented prospectively in ICI based clinical trials to develop reliable algorithms for palliative NSCLC treatment.
Journal ArticleDOI
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
Ye Li,Zhibo Zhang,Yi Hu,Xiang Yan,Qi Song,Guoqiang Wang,Runzhe Chen,Shunchang Jiao,Jinliang Wang +8 more
TL;DR: This study demonstrates that pretreatment NLR and dNLR from baseline are associated with the outcomes of advanced NSCLC patients treated with ICIs; however, it warrants further prospective studies.
References
More filters
Journal ArticleDOI
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Cancer statistics in China, 2015
Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He +8 more
TL;DR: Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Journal ArticleDOI
Inflammation and cancer
Lisa M. Coussens,Zena Werb +1 more
TL;DR: It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration.
Journal ArticleDOI
Cancer-related inflammation.
TL;DR: The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Related Papers (5)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more